Serum Concentrations of Fibroblast Growth Factors 19 and 21 in Women with Gestational Diabetes Mellitus: Association with Insulin Resistance, Adiponectin, and Polycystic Ovary Syndrome History

• Published in: PloS one Vol. 8; no. 11; p. e81190
• Main Authors: Wang, Dongyu, Zhu, Wenjing, Li, Jieming, An, Chongyou, Wang, Zilian
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 19.11.2013; Public Library of Science (PLoS)
• Subjects: Adiponectin; Adiponectin - blood; Adiponectin - genetics; Adult; Analysis; Anthropometry; Case-Control Studies; Correlation; Dextrose; Diabetes Complications - blood; Diabetes Complications - etiology; Diabetes Complications - physiopathology; Diabetes in pregnancy; Diabetes mellitus; Diabetes, Gestational - blood; Diabetes, Gestational - physiopathology; Enzyme-linked immunosorbent assay; Enzymes; Female; Fibroblast growth factors; Fibroblast Growth Factors - blood; Fibroblast Growth Factors - genetics; Gene Expression; Gestational Age; Gestational diabetes; Glucose; Glucose tolerance; Growth factors; Homeostasis; Humans; Insulin; Insulin - blood; Insulin - genetics; Insulin Resistance; Kinases; Medical research; Medicine, Experimental; Patients; Polycystic ovary syndrome; Polycystic Ovary Syndrome - blood; Polycystic Ovary Syndrome - complications; Polycystic Ovary Syndrome - physiopathology; Pregnancy; Pregnant women; Rodents; Serum levels; Stein-Leventhal syndrome; Triglycerides; Triglycerides - blood; Type 2 diabetes; Womens health; China
• DOI: 10.1371/journal.pone.0081190
• ISSN: 1932-6203

Fibroblast growth factor 19 (FGF19) and FGF21 are considered to be novel adipokines that improve glucose tolerance and insulin sensitivity. In the current study, we investigated serum FGF19 and FGF21 levels in patients with gestational diabetes mellitus (GDM) and explored their relationships with anthropometric and endocrine parameters. Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) in patients with GDM (n = 30) and healthy pregnant controls (n = 60) matched for maternal and gestational age. Serum FGF19 and FGF21 levels were correlated with anthropometric, metabolic, and endocrine parameters. Circulating levels of FGF19 were significantly reduced in patients with GDM relative to healthy pregnant subjects, whereas FGF21 levels were increased in GDM patients. Serum FGF19 levels independently and inversely correlated with insulin resistance (increased homeostasis model assessment of insulin resistance, HOMA-IR) and were positively related to serum adiponectin in both groups. In contrast, serum FGF21 levels independently and positively correlated with insulin resistance and serum triglycerides and were inversely related to serum adiponectin. In addition, in the combined population of both groups, those women with preconception polycystic ovary syndrome (PCOS) history had the lowest levels of FGF19, which were significantly lower than those in GDM patients without PCOS history and those in controls without PCOS history. Circulating FGF19 levels are reduced in GDM patients, in contrast with FGF21 levels. Both serum FGF19 and FGF21 levels are strongly related to insulin resistance and serum levels of adiponectin. Considering the different situation between FGF19 and FGF21, we suggest that reduced serum FGF19 levels could be involved in the pathophysiology of GDM, while increased serum FGF21 levels could be in a compensatory response to this disease.